Bisindoylmaleimide I enhances osteogenic differentiation.
10.1007/s13238-012-2027-4
- Author:
Fangfang ZHOU
1
;
Huizhe HUANG
;
Long ZHANG
Author Information
1. Department of Molecular Cell Biology and Centre for Biomedical Genetics, Leiden University Medical Center, Leiden, The Netherlands.
- Publication Type:Journal Article
- MeSH:
Animals;
Bone Morphogenetic Proteins;
metabolism;
Cell Differentiation;
drug effects;
Cell Line, Tumor;
Glycogen Synthase Kinase 3;
metabolism;
Glycogen Synthase Kinase 3 beta;
Indoles;
chemistry;
pharmacology;
Maleimides;
chemistry;
pharmacology;
Mesenchymal Stem Cells;
cytology;
metabolism;
Mice;
Osteoblasts;
cytology;
drug effects;
metabolism;
RNA Interference;
RNA, Small Interfering;
metabolism;
Signal Transduction;
drug effects;
Wnt Proteins;
metabolism;
beta Catenin;
antagonists & inhibitors;
genetics;
metabolism
- From:
Protein & Cell
2012;3(4):311-320
- CountryChina
- Language:English
-
Abstract:
The Wnt/β-catenin and bone morphogenetic proteins (BMPs) pathways play important roles in controlling osteogenesis. Using a cell-based kinase inhibitor screening assay, we identified the compound bisindoylmaleimide I (BIM) as a potent agonist of the cytosolic β-catenin accumulation in preosteoblast cells. Through suppressing glycogen synthase kinase 3β enzyme activities, BIM upregulated β-catenin responsive transcription and extended duration of BMP initiated signal. Functional analysis revealed that BIM promoted osteoblast differentiation and bone formation. The treatment of human mesenchymal stem cells with BIM promoted osteoblastogenesis. Our findings provide a new strategy to regulate mesenchymal stem cell differentiation by integration of the cellular signaling pathways.
